WO2024184812 - ANTI-CLDN6 ANTIBODIES AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2024/184812
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052127
International Filing Date
05.03.2024
Title **
[English]
ANTI-CLDN6 ANTIBODIES AND METHODS OF USE
[French]
ANTICORPS ANTI-CLDN6 ET PROCÉDÉS D'UTILISATION
Applicants **
BEONE MEDICINES I GMBH
Aeschengraben 27
4051 Basel, CH
BEONE GUANGZHOU BIOLOGICS MANUFACTURING CO., LTD.
No. 83 South Kangyao Road, Huangpu District, Guangzhou
Guangdong, Guangdong 510555, CN
Inventors
LI, Dan
4F, Tower D, No. 780 Cailun Road
Pilot Free Trade Zone, Pudong New Area
Shanghai 201203, CN
TANG, Xiaoyan
No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District
Beijing 102206, CN
LEI, Ming
No. 51 Rijing Road, China Pilot Free Trade
Zone, Pudong New Area
Shanghai 200131, CN
SHAO, Ting
No. 51 Rijing Road, China Pilot Free Trade
Zone, Pudong New Area
Shanghai 200131, CN
Priority Data
PCT/CN2023/079815
06.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2382 | |
| EPO | Filing, Examination | 13143 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 8885 |
Total: 25516 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CLDN6, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.[French]
La présente divulgation concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient à la CLDN6 humaine, une composition pharmaceutique comprenant ledit anticorps ou des fragments de liaison à l'antigène de celui-ci, et l'utilisation de l'anticorps ou de fragments de liaison à l'antigène de celui-ci ou de la composition pour le traitement d'une maladie, telle que le cancer.